Title: Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
Authors: Rathkopf, Dana E ×
Smith, Matthew R
de Bono, Johann S
Logothetis, Christopher J
Shore, Neal D
de Souza, Paul
Fizazi, Karim
Mulders, Peter F A
Mainwaring, Paul
Hainsworth, John D
Beer, Tomasz M
North, Scott
Fradet, Yves
Van Poppel, Hendrik
Carles, Joan
Flaig, Thomas W
Efstathiou, Eleni
Yu, Evan Y
Higano, Celestia S
Taplin, Mary-Ellen
Griffin, Thomas W
Todd, Mary B
Yu, Margaret K
Park, Youn C
Kheoh, Thian
Small, Eric J
Scher, Howard I
Molina, Arturo
Ryan, Charles J
Saad, Fred #
Issue Date: Nov-2014
Series Title: European urology vol:66 issue:5 pages:815-25
Article number: S0302-2838(14)00185-7
Abstract: Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asymptomatic patients with progressive mCRPC without prior chemotherapy.
ISSN: 0302-2838
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Organ Systems (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science